{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:58:25Z","timestamp":1790193505914,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["No. 2016YFC1302204"],"award-info":[{"award-number":["No. 2016YFC1302204"]}]},{"name":"National Key Research and Development Program of China","award":["No. 2017YFC1308600"],"award-info":[{"award-number":["No. 2017YFC1308600"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81872071"],"award-info":[{"award-number":["No. 81872071"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81672502"],"award-info":[{"award-number":["No. 81672502"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 31802142"],"award-info":[{"award-number":["No. 31802142"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81902664"],"award-info":[{"award-number":["No. 81902664"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing","doi-asserted-by":"publisher","award":["No. cstc2019jcyj-zdxmX0033"],"award-info":[{"award-number":["No. cstc2019jcyj-zdxmX0033"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for Central Universities of the Central South University","doi-asserted-by":"crossref","award":["No. XDJK2019C089"],"award-info":[{"award-number":["No. XDJK2019C089"]}],"id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012459","name":"Chongqing Graduate Student Research Innovation Project","doi-asserted-by":"publisher","award":["No.CYB18105"],"award-info":[{"award-number":["No.CYB18105"]}],"id":[{"id":"10.13039\/501100012459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012459","name":"Chongqing Graduate Student Research Innovation Project","doi-asserted-by":"publisher","award":["No. CYS18124"],"award-info":[{"award-number":["No. CYS18124"]}],"id":[{"id":"10.13039\/501100012459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"crossref","award":["No. SWU120009"],"award-info":[{"award-number":["No. SWU120009"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Lycorine hydrochloride (LH), an alkaloid extracted from the bulb of the\n                      <jats:italic>Lycoris radiata<\/jats:italic>\n                      , is considered to have anti-viral, anti-malarial, and anti-tumorous effects. At present, the underlying mechanisms of LH in gastric cancer remain unclear. MCL1, an anti-apoptotic protein of BCL2 family, is closely related to drug resistance of tumor. Therefore, MCL1 is considered as a potential target for cancer treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The effect of LH on gastric cancer was assessed in vitro (by MTT, BrdU, western blotting\u2026) and in vivo (by immunohistochemistry).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this study, we showed that LH has an anti-tumorous effect by down-regulating MCL1 in gastric cancer. Besides, we unveiled that LH reduced the protein stability of MCL1 by up-regulating ubiquitin E3 ligase FBXW7, arrested cell cycle at S phase and triggered apoptosis of gastric cancer cells. Meanwhile, we also demonstrated that LH could induce apoptosis of the BCL2-drug-resistant-cell-lines. Moreover, PDX (Patient-Derived tumor xenograft) model experiment proved that LH combined with HA14\u20131 (inhibitor of BCL2), had a more significant therapeutic effect on gastric cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The efficacy showed in our data suggests that lycorine hydrochloride is a promising anti-tumor compound for gastric cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-020-01743-3","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T13:04:09Z","timestamp":1604063049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Lycorine hydrochloride inhibits cell proliferation and induces apoptosis through promoting FBXW7-MCL1 axis in gastric cancer"],"prefix":"10.1186","volume":"39","author":[{"given":"Chongyang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaowei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaichao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaomin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"1743_CR1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"S EC","year":"2020","unstructured":"EC S, M N, HI G, van Grieken NC, F L. Gastric cancer. Lancet (London, England). 2020;396:635\u201348.","journal-title":"Lancet (London, England)"},{"key":"1743_CR2","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1038\/s41388-020-1241-4","volume":"39","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zhang J, Cheng A, et al. Gastric cancer: genome damaged by bugs. Oncogene. 2020;39:3427\u201342.","journal-title":"Oncogene"},{"key":"1743_CR3","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/s41419-019-2131-y","volume":"10","author":"W Li","year":"2019","unstructured":"Li W, Zhang X, Wu F, et al. Gastric cancer-derived mesenchymal stromal cells trigger M2 macrophage polarization that promotes metastasis and EMT in gastric cancer. Cell Death Dis. 2019;10:918.","journal-title":"Cell Death Dis"},{"key":"1743_CR4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ctrv.2018.05.010","volume":"69","author":"F Montagnani","year":"2018","unstructured":"Montagnani F, Crivelli F, Aprile G, et al. Long-term survival after liver metastasectomy in gastric cancer: systematic review and meta-analysis of prognostic factors. Cancer Treat Rev. 2018;69:11\u201320.","journal-title":"Cancer Treat Rev"},{"key":"1743_CR5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ags3.12060","volume":"2","author":"J Kitayama","year":"2018","unstructured":"Kitayama J, Ishigami H, Yamaguchi H, et al. Treatment of patients with peritoneal metastases from gastric cancer. Ann Gastroenterol Surg. 2018;2:116\u201323.","journal-title":"Ann Gastroenterol Surg"},{"key":"1743_CR6","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/bjc.2017.54","volume":"116","author":"Y Song","year":"2017","unstructured":"Song Y, Wang Y, Tong C, et al. A unified model of the hierarchical and stochastic theories of gastric cancer. Br J Cancer. 2017;116:973\u201389.","journal-title":"Br J Cancer"},{"key":"1743_CR7","doi-asserted-by":"crossref","first-page":"109278","DOI":"10.1016\/j.biopha.2019.109278","volume":"118","author":"M Jakubek","year":"2019","unstructured":"Jakubek M, Kejik Z, Kaplanek R, et al. Strategy for improved therapeutic efficiency of curcumin in the treatment of gastric cancer. Biomed Pharmacother. 2019;118:109278.","journal-title":"Biomed Pharmacother"},{"key":"1743_CR8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.canlet.2014.03.013","volume":"347","author":"Q Wu","year":"2014","unstructured":"Wu Q, Yang Z, Nie Y, Shi Y, Fan D. Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett. 2014;347:159\u201366.","journal-title":"Cancer Lett"},{"key":"1743_CR9","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.3748\/wjg.v17.i35.3986","volume":"17","author":"JH Wang","year":"2011","unstructured":"Wang JH, Du JP, Zhang YH, et al. Dynamic changes and surveillance function of prion protein expression in gastric cancer drug resistance. World J Gastroenterol. 2011;17:3986\u201393.","journal-title":"World J Gastroenterol"},{"key":"1743_CR10","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/35085008","volume":"2","author":"M Leist","year":"2001","unstructured":"Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol. 2001;2:589\u201398.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1743_CR11","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/1521-1878(200011)22:11<1007::AID-BIES7>3.0.CO;2-4","volume":"22","author":"SH Kaufmann","year":"2000","unstructured":"Kaufmann SH, Gores GJ. Apoptosis in cancer: cause and cure. BIOESSAYS. 2000;22:1007\u201317.","journal-title":"BIOESSAYS"},{"key":"1743_CR12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0092-8674(02)00625-6","volume":"108","author":"RW Johnstone","year":"2002","unstructured":"Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002;108:153\u201364.","journal-title":"Cell"},{"key":"1743_CR13","doi-asserted-by":"crossref","first-page":"12492","DOI":"10.1073\/pnas.1507491112","volume":"112","author":"H Park","year":"2015","unstructured":"Park H, Cho SY, Kim H, et al. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer. Proc Natl Acad Sci U S A. 2015;112:12492\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1743_CR14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","volume":"9","author":"RJ Youle","year":"2008","unstructured":"Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9:47\u201359.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1743_CR15","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/sj.onc.1210220","volume":"26","author":"JM Adams","year":"2007","unstructured":"Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. ONCOGENE. 2007;26:1324\u201337.","journal-title":"ONCOGENE"},{"key":"1743_CR16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pharmthera.2014.08.003","volume":"145","author":"J Belmar","year":"2015","unstructured":"Belmar J, Fesik SW. Small molecule mcl-1 inhibitors for the treatment of cancer. Pharmacol Ther. 2015;145:76\u201384.","journal-title":"Pharmacol Ther"},{"key":"1743_CR17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","volume":"17","author":"L Chen","year":"2005","unstructured":"Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17:393\u2013403.","journal-title":"Mol Cell"},{"key":"1743_CR18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","volume":"16","author":"A Ashkenazi","year":"2017","unstructured":"Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov. 2017;16:273\u201384.","journal-title":"Nat Rev Drug Discov"},{"key":"1743_CR19","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421\u20138.","journal-title":"Cancer Res"},{"key":"1743_CR20","volume":"8","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, He J, Li J, et al. Demethylzeylasteral inhibits cell proliferation and induces apoptosis through suppressing MCL1 in melanoma cells. Cell Death Dis. 2017;8:e3133.","journal-title":"Cell Death Dis"},{"key":"1743_CR21","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-07-4622","volume":"14","author":"AR Shoemaker","year":"2008","unstructured":"Shoemaker AR, Mitten MJ, Adickes J, et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res. 2008;14:3268\u201377.","journal-title":"Clin Cancer Res"},{"key":"1743_CR22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","volume":"10","author":"MF van Delft","year":"2006","unstructured":"van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if mcl-1 is neutralized. Cancer Cell. 2006;10:389\u201399.","journal-title":"Cancer Cell"},{"key":"1743_CR23","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1007\/s00018-008-8637-6","volume":"66","author":"C Akgul","year":"2009","unstructured":"Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci. 2009;66:1326\u201336.","journal-title":"Cell Mol Life Sci"},{"key":"1743_CR24","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1517\/13543784.2011.609167","volume":"20","author":"BA Quinn","year":"2011","unstructured":"Quinn BA, Dash R, Azab B, et al. Targeting mcl-1 for the therapy of cancer. Expert Opin Investig Drugs. 2011;20:1397\u2013411.","journal-title":"Expert Opin Investig Drugs"},{"key":"1743_CR25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202\u20138.","journal-title":"Nat Med"},{"key":"1743_CR26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/138955710791112604","volume":"10","author":"D Lamoral-Theys","year":"2010","unstructured":"Lamoral-Theys D, Decaestecker C, Mathieu V, et al. Lycorine and its derivatives for anticancer drug design. Mini-Rev Med Chem. 2010;10:41\u201350.","journal-title":"Mini-Rev Med Chem"},{"key":"1743_CR27","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1016\/j.bmc.2010.05.023","volume":"18","author":"JC Cedron","year":"2010","unstructured":"Cedron JC, Gutierrez D, Flores N, Ravelo AG, Estevez-Braun A. Synthesis and antiplasmodial activity of lycorine derivatives. Bioorg Med Chem. 2010;18:4694\u2013701.","journal-title":"Bioorg Med Chem"},{"key":"1743_CR28","first-page":"959","volume":"7","author":"JJ Nair","year":"2012","unstructured":"Nair JJ, van Staden J. Acetylcholinesterase inhibition within the lycorine series of Amaryllidaceae alkaloids. Nat Prod Commun. 2012;7:959\u201362.","journal-title":"Nat Prod Commun"},{"key":"1743_CR29","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.toxlet.2013.01.018","volume":"218","author":"Z Cao","year":"2013","unstructured":"Cao Z, Yu D, Fu S, et al. Lycorine hydrochloride selectively inhibits human ovarian cancer cell proliferation and tumor neovascularization with very low toxicity. Toxicol Lett. 2013;218:174\u201385.","journal-title":"Toxicol Lett"},{"key":"1743_CR30","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41419-018-1086-8","volume":"9","author":"K Zhang","year":"2018","unstructured":"Zhang K, Fu G, Pan G, et al. Demethylzeylasteral inhibits glioma growth by regulating the miR-30e-5p\/MYBL2 axis. Cell Death Dis. 2018;9:1035.","journal-title":"Cell Death Dis"},{"key":"1743_CR31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41392-020-0137-7","volume":"5","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, He J, Li Y, Lv S, Cui H. NUSAP1 potentiates chemoresistance in glioblastoma through its SAP domain to stabilize ATR. Signal Transduct Target Ther. 2020;5:44.","journal-title":"Signal Transduct Target Ther"},{"key":"1743_CR32","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3390\/cells8080774","volume":"8","author":"J Cao","year":"2019","unstructured":"Cao J, Zhao E, Zhu Q, et al. Tubeimoside-1 inhibits Glioblastoma growth, migration, and invasion via inducing Ubiquitylation of MET. Cells-Basel. 2019;8:774.","journal-title":"Cells-Basel"},{"key":"1743_CR33","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/s41416-019-0633-0","volume":"121","author":"G Zhang","year":"2019","unstructured":"Zhang G, Zhu Q, Fu G, et al. TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7\/c-MYC axis. Br J Cancer. 2019;121:1069\u201378.","journal-title":"Br J Cancer"},{"key":"1743_CR34","first-page":"70","volume":"1","author":"ZJ Jin","year":"1980","unstructured":"Jin ZJ. Addition in drug combination. Acta Pharmacol Sin. 1980;1:70\u20136.","journal-title":"Acta Pharmacol Sin"},{"key":"1743_CR35","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/jso.21344","volume":"100","author":"W Likui","year":"2009","unstructured":"Likui W, Qun L, Wanqing Z, et al. Prognostic role of myeloid cell leukemia-1 protein (mcl-1) expression in human gastric cancer. J Surg Oncol. 2009;100:396\u2013400.","journal-title":"J Surg Oncol"},{"key":"1743_CR36","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","volume":"8","author":"HE Ramsey","year":"2018","unstructured":"Ramsey HE, Fischer MA, Lee T, et al. A novel MCL1 inhibitor combined with Venetoclax rescues Venetoclax-resistant acute Myelogenous leukemia. Cancer Discov. 2018;8:1566\u201381.","journal-title":"Cancer Discov"},{"key":"1743_CR37","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359\u201386.","journal-title":"Int J Cancer"},{"key":"1743_CR38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2005.09.010","volume":"44","author":"W Sieghart","year":"2006","unstructured":"Sieghart W, Losert D, Strommer S, et al. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol. 2006;44:151\u20137.","journal-title":"J Hepatol"},{"key":"1743_CR39","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41416-020-0795-9","volume":"122","author":"A Bierbrauer","year":"2020","unstructured":"Bierbrauer A, Jacob M, Vogler M, Fulda S. A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma. Br J Cancer. 2020;122:1544\u201351.","journal-title":"Br J Cancer"},{"key":"1743_CR40","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.molcel.2006.02.009","volume":"21","author":"U Maurer","year":"2006","unstructured":"Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell. 2006;21:749\u201360.","journal-title":"Mol Cell"},{"key":"1743_CR41","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1158\/0008-5472.CAN-16-3242","volume":"77","author":"J Tong","year":"2017","unstructured":"Tong J, Wang P, Tan S, et al. Mcl-1 degradation is required for targeted therapeutics to eradicate Colon Cancer cells. Cancer Res. 2017;77:2512\u201321.","journal-title":"Cancer Res"},{"key":"1743_CR42","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.cell.2005.06.009","volume":"121","author":"Q Zhong","year":"2005","unstructured":"Zhong Q, Gao W, Du F, Wang X. Mule\/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of mcl-1 and regulates apoptosis. CELL. 2005;121:1085\u201395.","journal-title":"CELL"},{"key":"1743_CR43","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1128\/MCB.00620-06","volume":"27","author":"Q Ding","year":"2007","unstructured":"Ding Q, He X, Hsu JM, et al. Degradation of mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol. 2007;27:4006\u201317.","journal-title":"Mol Cell Biol"},{"key":"1743_CR44","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature09732","volume":"471","author":"H Inuzuka","year":"2011","unstructured":"Inuzuka H, Shaik S, Onoyama I, et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. NATURE. 2011;471:104\u20139.","journal-title":"NATURE"},{"key":"1743_CR45","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature09779","volume":"471","author":"IE Wertz","year":"2011","unstructured":"Wertz IE, Kusam S, Lam C, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 2011;471:110\u20134.","journal-title":"Nature"},{"key":"1743_CR46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41418-019-0339-0","volume":"27","author":"X Wu","year":"2020","unstructured":"Wu X, Luo Q, Zhao P, et al. JOSD1 inhibits mitochondrial apoptotic signalling to drive acquired chemoresistance in gynaecological cancer by stabilizing MCL1. Cell Death Differ. 2020;27:55\u201370.","journal-title":"Cell Death Differ"},{"key":"1743_CR47","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1073\/pnas.1814742116","volume":"116","author":"X Wu","year":"2019","unstructured":"Wu X, Luo Q, Zhao P, et al. MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer. Proc Natl Acad Sci U S A. 2019;116:2961\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1743_CR48","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41467-017-02693-9","volume":"9","author":"S Zhang","year":"2018","unstructured":"Zhang S, Zhang M, Jing Y, et al. Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors. Nat Commun. 2018;9:215.","journal-title":"Nat Commun"},{"key":"1743_CR49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature08646","volume":"463","author":"M Schwickart","year":"2010","unstructured":"Schwickart M, Huang X, Lill JR, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature. 2010;463:103\u20137.","journal-title":"Nature"},{"key":"1743_CR50","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00280-008-0697-7","volume":"62","author":"SH Wei","year":"2008","unstructured":"Wei SH, Dong K, Lin F, et al. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting mcl-1 gene in pancreatic carcinoma cell. Cancer Chemother Pharmacol. 2008;62:1055\u201364.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1743_CR51","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13046-019-1227-7","volume":"38","author":"X Xia","year":"2019","unstructured":"Xia X, Huang C, Liao Y, et al. Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide. J Exp Clin Cancer Res. 2019;38:220.","journal-title":"J Exp Clin Cancer Res"}],"updated-by":[{"DOI":"10.1186\/s13046-022-02503-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000}}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-020-01743-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-020-01743-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-020-01743-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T02:06:32Z","timestamp":1666058792000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-020-01743-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["1743"],"URL":"https:\/\/doi.org\/10.1186\/s13046-020-01743-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-38705\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-38705\/v1","asserted-by":"object"}]},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,30]]},"assertion":[{"value":"28 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13046-022-02503-1","URL":"https:\/\/doi.org\/10.1186\/s13046-022-02503-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were conducted in accordance with the Guidelines for Animal Health and Use (Ministry of Science and Technology of China, 2006). The tumor mass of GAM-AD was from The Ninth People\u2019s Hospital of Chongqing. With the consent of the patient\u2019s family, we carried out the PDX model experiment. Besides, the patient\u2019s privacy has been fully protected.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The corresponding author and all the co-authors have agreed to the publication of the manuscript to Journal of Experimental and Clinical Cancer Research as a research article and declare that they have no conflict of interest as to the results presented.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"230"}}